Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2005
12/15/2005WO2005097084A3 Calcium salts for the treatment of psoriasis, dermatitis and dandruff
12/15/2005WO2005094305A3 Combination therapy for weight management
12/15/2005WO2005090570A9 Therapeutic compositions and methods for treating diseases that involve angiogenesis
12/15/2005WO2005089752A3 Tetra-cyclic carboline derivatives for inhibiting angiogenesis
12/15/2005WO2005087751A3 Substituted hydroxyethylamine aspartyl protease inhibitors
12/15/2005WO2005087714A3 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
12/15/2005WO2005086944A3 Combination therapies using leptomycin b
12/15/2005WO2005084230A3 Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
12/15/2005WO2005082366A8 Nk-1 receptor antagonists anesthesia recovery
12/15/2005WO2005082358A3 Use of beta-lapachone as a broad spectrum anti-cancer agent
12/15/2005WO2005080357A3 Oxazole derivatives, preparation and therapeutic use therof
12/15/2005WO2005077353A8 Dichloroacetate in combination with an inotrope for cardioprotection
12/15/2005WO2005070945A8 Novel aminoglycoside antibiotic effective against methicillin resistant staphylococcus aureus (mrsa)
12/15/2005WO2005065318A3 Effervescent oral opiate dosage form
12/15/2005WO2005065266A3 Di-substituted pyrrolotriazine compounds
12/15/2005WO2005062874A3 Compounds and compositions for delivering active agents
12/15/2005WO2005060665A3 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
12/15/2005WO2005060571A3 Antiprotozoal imidazopyridine compounds
12/15/2005WO2005056572A3 Clustered multi-antigenic carbohydrate constructs, methods for their preparation and uses thereof
12/15/2005WO2005055952A3 Synergistic anti-cancer compositions
12/15/2005WO2005046592A3 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
12/15/2005WO2005046565A3 Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
12/15/2005WO2005046564A3 Diagnosis and treatment of liver fibrosis
12/15/2005WO2005044195A3 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
12/15/2005WO2005039554A3 Therapeutic use of methionine for the treatment or prevention of mucositis
12/15/2005WO2005039507A3 Antimicrobial and antiviral compounds
12/15/2005WO2005034874A3 Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
12/15/2005WO2005030120A3 Antiangiogenic agents
12/15/2005WO2005021706A3 Delivery of compounds with rehydrated blood cells
12/15/2005WO2005021626A3 Antimicrobial acrylic polymer
12/15/2005WO2005018576A3 N-desmethyl-n-substituted-11-deoxyerythromycin compounds
12/15/2005WO2005018550B1 Enhancement of magnesium uptake in mammals
12/15/2005WO2005017190A3 Mitotic kinesin inhibitors
12/15/2005WO2005016252A3 Phosphorus-containing macrocycles
12/15/2005WO2005012318A3 Substituted fused heterocyclic c-glycosides
12/15/2005WO2005011597A8 Compounds and compositions as protein kinase inhibitors
12/15/2005WO2005011472A3 Reduction of adverse inflammation
12/15/2005WO2005007832A3 System for external control of oncolytic virus replication
12/15/2005WO2004105699A3 Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
12/15/2005WO2004101764A3 Methods of modulating metastasis and skeletal related events resulting from metastases
12/15/2005WO2004100864A3 Treatment kit which assists with antibiotic therapy for intracellular infectious diseases
12/15/2005WO2004089309A3 Conposition and methods for inhibiting fungal growth and transference
12/15/2005WO2004083258A3 Branched water-soluble polymers and their conjugates
12/15/2005WO2004078734A8 TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
12/15/2005WO2004066931A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
12/15/2005WO2004062616A3 Method of treating cognitive decline due to sleep deprivation and stress
12/15/2005WO2004056317A8 Compositions for the treatment and prevention of nephropathy
12/15/2005WO2004014313A3 Combination pharmaceutical agents as inhibitors of hcv replication
12/15/2005WO2004000211A3 Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
12/15/2005WO2003061597A3 Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
12/15/2005WO2002083921A8 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
12/15/2005US20050277775 Process for the preparation of keto compounds
12/15/2005US20050277763 For cancer therapy
12/15/2005US20050277700 Non-halogenated hydroxyalkyl-substituted phenol compounds, antimicrobial compositions containing the same, and methods of using the same
12/15/2005US20050277699 Method of decreasing sebum production and pore size
12/15/2005US20050277698 Utilizing anionic polymer additive to attenuate adverse effects associated with topical ophthalmic use of neuroprotective agents; well tolerated, nontoxic
12/15/2005US20050277697 Method for treatment of the common cold, flu, and virus symptoms
12/15/2005US20050277696 Novel use of cytotoxic drugs for treatment and prophylasxis of aging diseases by reversing the loss of elasticity of epithelial cells due to aging
12/15/2005US20050277695 Topically administering NF- kappa B inhibitors, adhesion antagonists, retinoids, tetracyclines; reduce and/or eliminate scarring, inflammatory reaction that accompanies acne
12/15/2005US20050277694 Topical compositions and methods for epithelial-related conditions
12/15/2005US20050277693 Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
12/15/2005US20050277691 Pravastatin pharmaceutical formulations and methods of their use
12/15/2005US20050277690 Small molecules for treatment of hypercholesterolemia and related diseases
12/15/2005US20050277689 carvedilol mandelate or carvedilol sulfate salt for treating hypertension, congestive heart failure or angina cardiovascular disorders
12/15/2005US20050277688 Napadisylate salt formation of 2-[(S)-1-(8-methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide in an aqueous isopropanol or ethanol solution; combined with a beta 2 adrenergic receptor agonist or a steroidal anti-inflammatory agent; COPD, asthma; muscarinic receptor antagonists, bronchodilators
12/15/2005US20050277687 synergistic mixture of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (Tapentadol) with celecoxib or rofecoxib; enantiomer; racemic mixture; smaller dosages so fewer side effects
12/15/2005US20050277686 Benzimidazole compounds for regulating IgE
12/15/2005US20050277685 peroxisome proliferator activated receptor agonist such as (2R)-2-(3-{[3-(4-chlorophenoxy)-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl]methyl}phenoxy)butanoic acid, used for treatment and control of metabilic disorders
12/15/2005US20050277684 Effective under oxidative cellular environment; inhibits the growth of prostate cells by inhibiting DNA synthesis, more particularly by DNA cleavage; TG-25; prostate cancer; synergystic use with other agents like radiation, chemotherapeutic, an inhibitor of DNA repair, etoposide, or anticancer agents
12/15/2005US20050277683 Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use
12/15/2005US20050277682 Therapeutic formulations of desoxyepothilones
12/15/2005US20050277681 N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
12/15/2005US20050277680 tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents
12/15/2005US20050277679 Antidiabetic agents; dietetics; hypoglycermic agents; stable, high melting crystalline material, suitable for bulk preparation and handling
12/15/2005US20050277678 5-(4-Fluorophenyl)-1-(4-methylsulfoximinylphenyl)-3-trifluoromethyl-1H-pyrazole; prostaglandin and cyclooxygenase inhibitor; antiinflammatory, analgesic, and antipyretic agent
12/15/2005US20050277677 Method for treating emesis with ghrelin agonists
12/15/2005US20050277676 M3muscarinic acetylcholine receptor antagonists
12/15/2005US20050277675 water solubilizer for nanocarbons contains a surfactant which can form a spherical micelle vesicle having a diameter of 50-2,000 nm in a water solution or a water-soluble polymer having a weight-average molecular weight of 10,000-50,000,000 as an active constituent
12/15/2005US20050277673 such as 4-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid; serotonin receptor agonist; antidepressant, anxiolytic agent, analgesic, cognition activator; less toxicity, good absorption, and metabolic stability
12/15/2005US20050277672 such as 1-{[4-({[(3-isopropyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)carbonyl]amino}methyl)piperidin-1-yl]methyl}cyclopentanecarboxylic acid; serotonin receptor agonist; antidepressant, anxiolytic agent, analgesic, cognition activator; less toxicity, good absorption, and metabolic stability
12/15/2005US20050277671 Benzimidazolone carboxylic acid derivatives
12/15/2005US20050277670 Chemokine receptor binding compounds
12/15/2005US20050277668 viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide
12/15/2005US20050277666 Process of preparing N-ureidoalkyl-piperidines
12/15/2005US20050277665 e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes
12/15/2005US20050277664 Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation
12/15/2005US20050277663 3-Aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides
12/15/2005US20050277662 such as: 1-(2, 4-difluorobenzyl) -N-hydroxy-3-(morpholin-4-ylmethyl)-1H-pyrrolo[2,3-c]pyridine-5-carboxamide; acquired immunodeficiency syndrome ("AIDS"), and AIDS related complex ("ARC")
12/15/2005US20050277661 Inhibitors of the HIV integrase enzyme
12/15/2005US20050277659 Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists
12/15/2005US20050277658 Such as aurora-2 kinase or c-kit kinase; anticancer agents; based on benzo(4,5)furo(3,2-d)pyrimidine, 9-thia-1,5,7-triazafluorene, or pyrimido(5,4-b)indole rings; e.g. 6,7-dimethoxy-4-(4-(benzodioxol-5-ylmethylaminothiocarbonyl)-piperazin-1-yl)-5H-Pyrimido(5,4-b)indole
12/15/2005US20050277657 Method of protection of biologically active essential oils and pharmaceutical composition for weight control and enhance fat burning in adults, adolescents and children
12/15/2005US20050277656 Combination comprising docetaxel and a CDK inhibitor
12/15/2005US20050277655 Pyrazolopyrimidines
12/15/2005US20050277654 4,5-Disubstituted-2-aryl pyrimidines
12/15/2005US20050277653 Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
12/15/2005US20050277652 Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide
12/15/2005US20050277651 Reacting ziprasidone with hydrochloric acid in solvent; salt formation; drying
12/15/2005US20050277650 Process for preparing aripirazole hydrate
12/15/2005US20050277649 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors; potentiation; diabetes and obesity; 2-(4-{4-[1-(6-chloro-pyridin-3-yl)cyclopropylmethyl]-2-(R)-methyl-piperazine-1-sulfonyl}phenyl)-1,1,1-trifluoro-propan-2-ol
1 ... 4432 4433 4434 4435 4436 4437 4438 4439 4440 4441 4442 4443 4444 4445 4446 4447 4448 4449 4450 4451 4452 ... 7860